Compare Recursion Pharmaceuticals Inc (RXRX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Charles Schwab Corporation Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $4.21 (market cap $2.14B), while Charles Schwab Corporation Common Stock trades at $96.75 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 78.3× Recursion Pharmaceuticals Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| RXRX | SCHW | |
|---|---|---|
Market Cap | $2.14B | $167.52B |
Volume | 30,789,535 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $6.79 | $113.65 |
52-Week Low | $2.84 | $85.35 |
Typical Hold Time | 22 Days | 85 Days |
Enterprise Value | $1.66B | $153.97B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Charles Schwab (SCHW) trades at $95.58, down 1.26% today, amid bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.62 exceeding expectations of $1.56, while revenue grew to $23.92B in 2025. Analyst consensus remains bullish with a $119.92 price target, though technical indicators show selling pressure with RSI at oversold levels and bearish moving average alignment.
SCHW presents a compelling value opportunity with attractive valuation metrics (P/E 17.64) and robust profitability (ROE 22.45%), but faces near-term technical headwinds and market volatility risks. The company's expansion into AI integration and Texas Stock Exchange listing provides growth catalysts, though investors should monitor interest rate sensitivity and competitive pressures in the brokerage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
